Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases
Clinical Trials: Atherosclerosis
A listing of clinical trials currently looking for volunteers to enroll in Atherosclerosis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Birmingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fairhope : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntsville : Heart Center Research LLC
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
View More »
Mobile : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Alaska
Anchorage : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Arizona
Chandler : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Glendale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Phoenix : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Phoenix : St. Luke's Hospital-Phoenix
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Phoenix : Mayo Clinic - Arizona
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
View More »
Scottsdale : Scottsdale Healthcare Shea
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Tucson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Arkansas
Hot Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Little Rock : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Little Rock : Arkansas Heart Hospital
The OMEGA Clinical Trial
California
Santa Ana : Coastal Multi-Specialty Research
Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
View More »
Carmichael : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fullerton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Huntington Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lancaster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Long Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Los Angeles : University of Southern California
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Los Gatos : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mission Viejo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mountain View : El Camino Hospital / ACS Research Group, Inc.
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Mountain View : Fogarty Clinical Research Inc.
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Newport Beach : Hoag Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Northridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oceanside : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orange : St. Joseph Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Orangevale : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Spring : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palm Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Redondo Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sacramento : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Diego : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Diego : Kaiser Foundation Hospital-San Diego
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
San Diego : VA San Diego Health Care Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
San Francisco : San Francisco Veterans Affairs Medical Center
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Santa Clara : Abbott Vascular
The ABSORB BTK (Below The Knee) Clinical Investigation
Santa Rosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Torrance :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Torrance : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tustin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Visalia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vista : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Walnut Creek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Westlake Village : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Colorado
Aurora : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Colorado Springs :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Denver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Longmount : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Connecticut
Delaware
Newark : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida
Aventura : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Boynton Beach : Palm Beach Heart Institute, LLC - Zasa Clinical Research
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Clearwater : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Clearwater : Heart and Vascular Institute of Florida
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Defuniak Springs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Doral : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gainesville :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Hollywood : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Jacksonville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jacksonville : Jacksonville Center for Clinical Research
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Jacksonville Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jupiter : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miami : Baptist Cardiac and Vascular Institute
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Miami Beach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Naples : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orlando : Florida Hospital
The OMEGA Clinical Trial
Pinellas Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Port Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Port Orange : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sarasota : Sarasota Memorial Hospital
The OMEGA Clinical Trial
South Miami : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallahassee : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tampa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wellington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Georgia
Savannah : Memorial Health University Medical Center
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis (IRISS)
View More »
Athens : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Atlanta : Saint Joseph Research Institute
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Atlanta : Piedmont Heart Institute
Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
Augusta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Covington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cumming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Macon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roswell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hawaii
Honolulu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Honolulu : Hawaii Permanente Medical Group - Kaiser
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Idaho
Boise : St. Luke's Idaho Cardiology
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Illinois
Chicago : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chicago : Northwestern University Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Chicago : Rush University Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Chicago : Northwestern University
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Jerseyville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Lombard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Springfield : St. John's Hospital and Memorial Medical Center/ Prairie Heart Cooperative
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Springfield : Southern Illinois University-Memorial Medical Center
The OMEGA Clinical Trial
Indiana
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Evansville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fort Wayne : Parkview Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Indianapolis :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Indianapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Indianapolis : The Care Group, LLC
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Indianapolis : St. Vincent's Hospital
The OMEGA Clinical Trial
Iowa
Ames : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Waterloo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kansas
Lansing : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Overland Park : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Topeka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wichita : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kentucky
Lexington : Central Baptist Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Lexington : St. Joseph Hospital
The OMEGA Clinical Trial
Louisville : University of Louisville
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Madisonville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Owensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louisiana
Baton Rouge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Covington : TCA Research LLC
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Houma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lafayette : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mandeville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Metairie : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Orleans : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Orleans : Ochsner Clinic Foundation
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Opelousas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Shreveport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winnsboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zachary : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Maine
Beltsville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Maine Medical Center
The OMEGA Clinical Trial
Maryland
Towson : Spectrum Clinical Research, Inc.
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)
Towson : Spectrum Clinical Research, Inc.
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
View More »
Baltimore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Baltimore : Johns Hopkins Bayview Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Baltimore : Sinai Center for Thrombosis Research
Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis
Baltimore : Union Memorial Hospital
The OMEGA Clinical Trial
Bethesda : Cardiovascular and Pulmonary Branch (CPB) of NIH
Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease
Bethesda : Suburban Hospital
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Hyattsville :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Lutherville Timonium : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nottingham : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massachusetts
Boston :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Boston : Massachusetts General Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Boston : Massachusetts General Hospital
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
Boston : Massachusetts General Hospital
Subclinical Atherosclerosis in HIV-infected Patients
Burlington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Fall River : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haverhill :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Haverhill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Michigan
Ann Arbor : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ann Arbor : University of Michigan Health System
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Chelsea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Detroit : Detroit Medical Center (DMC) Cardiovascular Institute
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Flint : McLaren Regional Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Kalamazoo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Midland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petoskey : Cardiac and Vascular Research Center of Northern Michigan
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Royal Oak : William Beaumont Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Royal Oak : William Beaumont Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Saginaw : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Troy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wyoming : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minnesota
Duluth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Duluth : St. Mary's Duluth Clinic Regional Heart Center
The OMEGA Clinical Trial
Fridley : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Minneapolis :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Minneapolis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Minneapolis : Abbott Northwestern Hospital
The OMEGA Clinical Trial
Rochester : Mayo Clinic
Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III
St. Cloud : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mississippi
Hattiesburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Picayune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Missouri
Chesterfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kansas City :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Kansas City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Springfield : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Louis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Louis : St. John's Mercy Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Nebraska
Grand Island : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lincoln : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Omaha : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Omaha : Alegent Research Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
New Hampshire
Lebanon : Dartmouth Hitchcock Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Newington :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
New Jersey
Camden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Camden : Our Lady of Lourdes Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Cherry Hill : Our Lady of Lourdes Medical Center
The OMEGA Clinical Trial
Freehold : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Brunswick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Ocean : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pomona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Mexico
Albuquerque : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Albuquerque : Presbyterian Hospital
The OMEGA Clinical Trial
New York
Albany : Albany Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Binghamton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buffalo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Buffalo : Millard Fillmore Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Buffalo : Millard Fillmore Hospital
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
View More »
Buffalo : Buffalo Heart Group
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Endwell : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mineola : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New York :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
New York : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New York : Lenox Hill Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : Columbia Presbyterian Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : NYU Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
New York : Mount Sinai School of Medicine
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
North Massapequa :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Rochester : University of Rochester-Strong Memorial Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Roslyn : St. Francis Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Williamsville : Buffalo Cardiology & Pulmonary Associates
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
North Carolina
Raleigh : Rex Healthcare
ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study
Raleigh : Rex Healthcare
TRANSLATE- Treatment with ADP receptor inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry
View More »
Asheboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charlotte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Durham : Duke University Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Greensboro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greensboro : LeBauer Cardiovascular Research Foundation
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hickory : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Raleigh : WakeMed Health and Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Raleigh : Wake Medical Center
The OMEGA Clinical Trial
Rocky Mount : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salisbury : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sanford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Statesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winston Salem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Winston-Salem : Forsyth Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
North Dakota
Fargo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fargo : Sanford Heart Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Ohio
Akron : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Cincinnati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cincinnati : Sterling Research Group, Ltd.
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Cincinnati : Good Samaritan Hospital
The OMEGA Clinical Trial
View More »
Cincinnati : The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital
The OMEGA Clinical Trial
Cleveland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cleveland : Cleveland Clinic Foundation
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Columbus : Ohio State University
Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)
Columbus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbus : Riverside Methodist Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Columbus : Ohio State University Medical Center
The OMEGA Clinical Trial
Columbus : Riverside Methodist Hospital
The OMEGA Clinical Trial
Marion : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toledo : Mercy St. Vincent Medical Center
The OMEGA Clinical Trial
Toledo : The Toledo Hospital
The OMEGA Clinical Trial
Oklahoma
Bartlesville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oklahoma City : South Oklahoma Heart Research
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Oklahoma City : Oklahoma Heart Hospital
The OMEGA Clinical Trial
Tulsa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oregon
Portland :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Portland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Portland : Oregon Health and Science University Stroke Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pennsylvania
Abington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Allentown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Altoona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beaver : Heritage Valley Health System
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Bridgeville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Erie : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Harrisburg : Pinnacle Health Cardiovascular Insititute
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Hershey : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Philadelphia : Penn Presbyterian Medical Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Philidelphia : Presbyterian University of Pennsylvania Medical Center
The OMEGA Clinical Trial
Pittsburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pittsburgh : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pittsburgh : University of Pittsburgh Medical Center (UPMC)
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pittsburgh : University of Pittsburgh Physicians Division of Vascular Surgery
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Pottstown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sayre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tipton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uniontown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wyomissing : Berks Cardiologists
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Yardley : St. Mary Medical Center
The OMEGA Clinical Trial
Rhode Island
Cumberland : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Providence : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Carolina
Anderson : Anderson Area Medical Center
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
Anderson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Charleston : Medical University of South Carolina Hospital
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Charleston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Columbia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Greenville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Greer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mt. Pleasant : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ninety Six : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Orangeburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rock Hill : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Varnville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
South Dakota
Rapid City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sioux Falls : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sioux Falls : North Central Heart Institute
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Sioux Falls : Sanford Research / USD
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Tennessee
Germantown : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Germantown : The Stern Cardiovascular Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Johnson City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kingsport : Wellmont Holston Valley Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Knoxville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Knoxville : Mercy Medical Center West
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Knoxville : Mercy Medical West/Turkey Creek Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Memphis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Memphis : Baptist Memorial Hospital
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Texas
Dallas : Research Across America
Atherosclerotic Plaque Research Study
View More »
Allen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austin : Austin Heart, P.A.
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Beaumont : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dallas : Veterans Affairs North Texas Health Care Systems
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
Dallas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dallas : Dallas Veteran's Administration Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Dallas : Presbyterian Heart Institute
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Dallas : Dallas VA Medical Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Gonzales : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houston :
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Houston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Houston : St. Luke's Episcopal Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Houston : Baylor College of Medicine
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
Irving : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lake Jackson : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leander : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Livingston : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lufkin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marshall : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
McKinney : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Odessa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pasadena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Plano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Antonio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Temple : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Waco : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Webster : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Utah
Bountiful : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Layton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salt Lake City : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vermont
Virginia
Danville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ettrick : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Norfolk : Chesapeake General Hospital/Sentara Norfolk General Hospital
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Richmond : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Richmond : St. Mary's Hospital / Virginia Cardiovascular Specilists
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Roanoke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Washington
Port Orchard : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Renton : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seattle : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seattle : University of Washington Coronary Atherosclerosis Research Lab
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
Spokane : Deaconess Medical Center
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
View More »
Tacoma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tacoma : MultiCare Health System Research Institute / Cardiac Study Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Yakima : Yakima Heart Center
Using Magnetic Resonance Imaging to Evaluate Carotid Artery Plaque Composition in People Receiving Cholesterol-Lowering Medications (The CPC Study)
West Virginia
Wisconsin
Madison : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madison : University of Wisconsin
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Milwaukee : St. Luke's Medical Center - Milwaukee
Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)
Argentina
Buenos Aires : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Caba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Corrientes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Formosa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Posadas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Rosario : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Miguel de Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Salvador de Jujuy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Fe : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tucuman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Australia
Bateman : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Garran : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Geelong : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gosford : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Heidelberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Hobart : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Joondalup : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kogarah : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Liverpool : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Melbourne : The Alfred
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Melbourne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Perth : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Southport : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Austria
Linz : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Salzburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Stefan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vienna : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wien : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belgium
Aalst : Onze Lieve Vrouw Ziekenhuis
Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Aalst : OLV Ziekenhuis Aalst
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
Antwerp : AZ Middelheim
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
Bonheiden : Imelda Ziekenhuis
The OMEGA Clinical Trial
Brussels : Abbott Vascular International BVBA
ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System
View More »
Edegem : Universitair Ziekenhuis Antwerpen
The OMEGA Clinical Trial
Gent : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gent : Universitair Ziekenhuis Gent
The OMEGA Clinical Trial
Hasselt : Virga Jesse Ziekenhuis
The OMEGA Clinical Trial
Brazil
Belo Horizonte : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Belo Horizonte : Hospital Felicio Rocho
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Blumenau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Campinas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Campo Grande : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Curitiba : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florianópolis : Clinica Coris Medicina Avançada /Baia Sul Medical Center
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Goiania : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Passo Fundo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pelotas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Porto Alegre : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Recife : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Jose do Rio Preto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sao Paulo : Heart Institute
Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe
São Paulo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
São Paulo : Hospital Santa Marcelina de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Irmandade Santa Casa de Misericórdia de São Paulo
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
São Paulo : Instituto Dante Pazzanese de Cardiologia
Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions
Uberlândia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Canada
Calgary : Foothills Medical Centre
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cambridge : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Drummondville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gatineau : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lachine : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Laval : Centre de Santé et de Services Sociaux de Laval
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
London : London Health Sciences Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Loretteville : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montreal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montreal : Montreal General Hospital Research Institute
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Montreal : Montreal Heart Institute
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Montreal : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Mount Pearl : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Quebec : Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ)
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Québec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saskatoon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sherbrooke : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. John : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. John's : St. John Health Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
St-Charles-Borromée : CSSS du Nord de Lanaudière
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Ste-Foy : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toronto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Toronto : St. Michael's Hospital
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Trois-Rivières : Centre Hospitalier Régional de Trois-Rivières
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Victoria : Victoria Heart Institute Foundation
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
China
Beijing : Cardiovascular Institute and Fu Wai Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Beijing : Peking Union Medical College Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Beijing : Peking University First Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Beijing : The Chinese People's Liberation Army General Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Beijing : Chinese PLA General Hospital
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
View More »
Chengdu : Huaxi Hospital of Sichuan University
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Daqing : Daqing General Oil Field Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Guangzhou : Guangdong Cardiovascular Institute of Guangdong Provincial Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Guangzhou : Guangdong Nanfang Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Harbin : The 2nd Affiliated Hospital of Harbin Medical University
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Nanjing : Nanjing First Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Shanghai : Shanghai 6th People's Hospital, Jiaotong University
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Shanghai : Shanghai Chest Hospital of Jiaotong University
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Shen Yang : General Hospital of SY Military Institute
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Tianjin : TEDA International Cardiovascular Hospital
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Xi'an : Xijing Hospital, Fourth Military Medical University
A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
Colombia
Baranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Barranquilla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bogotá : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucaramanga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cartagena : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Florida Blanca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Czech Republic
Kladno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Louny : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Marianske lazne : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ostrava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pardubice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Plzen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Semily : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slany : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Labem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Usti nad Orlici : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Denmark
Aarhus C : Dep. of Dermatology
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Estonia
Saku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tallinn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Viljandimaa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Võru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Finland
Pori : Satakunta Central Hospital
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
France
Bordeaux : Hôpital Cardiologique du Haut-Lévesque
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Limoges : CHU Limoges
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Montpellier : Höpital Gui de Chauliac
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Nantes : CHU Hôpital Guillaume et René Laënnec
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Nice : Hôpital Saint-Roch
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
View More »
Paris : Hôpital Lariboisière
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Pessac : Hospitaux du Haut Leveque
The OMEGA Clinical Trial
Toulouse : CHU Toulouse
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Toulouse : Centre Hospitalier Universitaire de Toulouse Rangueil
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Toulouse : Clinique Pasteur
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Toulouse : Centre Hôpital Universitaire Rangueil
The OMEGA Clinical Trial
Toulouse Cedex 3 : Clinique Pasteur
The OMEGA Clinical Trial
Germany
Anderbeck : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Augsburg : Klinikum Augsburg
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Bad : Kerckhoff Heart and Thoraxcenter
The OMEGA Clinical Trial
Bad Segeberg : Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH
The OMEGA Clinical Trial
Berlin : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Dresden : Universitätsklinikum Dresden
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Düsseldorf : Universitätsklinikum Düsseldorf
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Erlangen : Universitätsklinikum Erlangen
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Essen : Universitätsklinikum Essen
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Essen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Freiburg : Universitätsklinikum Freiburg
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Fulda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamburg : Asklepios Klinik Altona
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Heidelberg : Universitätsklinikum Heidelberg
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Heidelberg : Universitaetsklinikum Heidelberg
The OMEGA Clinical Trial
Kiel : UKSH Campus Kiel
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Krefeld : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Mainz : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Rednitzhembach : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ulm : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Wolmirstedt : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hungary
Budapest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gyula : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Miskolc : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nyiregyháza : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pecs : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Szeged : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Szentes : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Zalaegerszeg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
India
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ahmedabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bangalore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bengaluru : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bikaner : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Chennai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ghaziabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Guntur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hyderabad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Jaipur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kochi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lucknow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ludhiana : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Madurai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Manipal : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagpur : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nampally : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nashik : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nellore : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Delhi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pune : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rajasthan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Surat : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vadodara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vijayawada : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Israel
Jerusalem : Novartis Investigative Site
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
Italy
Ancona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bergamo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Brescia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Casorate Primo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Catanzaro : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cortona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Foggia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Massa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Milano : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Monserrato : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Montichiari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Napoli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Novara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Palermo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pavia : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pisa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pozzilli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Roma : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Daniele Del Friuli : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Santa Maria Capua Vetere : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sassari : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Treviglio : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Verona : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Japan
Amagasaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bunkyo-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Chiyoda-ku : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fuchu-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Fujioka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Funabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hitachi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ichinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Itabashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kasuga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kitakyushu-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komatsushima : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kumamoto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kusatsu-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kyoto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Matsudo-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nagoya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nishinomiya : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogaki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ogura-gun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Osaka : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sendai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seto : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takarazuka-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takasaki-city : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Takatsuki : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tokorozawa : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yukuhashi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Korea, Republic of
Busan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Busan : Inje University Pusan Paik Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Daegu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Daegu : Yeungnam University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Daejeon : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Daejon : Eulji University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Deagu : Kyungpook National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Gwangju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Gwangju : Chonnam National University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Iksan : Wonkwang University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Inchon : Inha University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Pusan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pusan : Dong-A University Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : AMC
Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Seoul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seoul : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Seoul : Kyung Hee University Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Seoul Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Eulji Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Asan Medical Center
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Boramae Hospital
Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis
Seoul : Cardiovascular center, Seoul St. Mary's hospital
The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)
Uijeongbu-Si : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Wonju : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Latvia
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Riga : P. Stradins University Hospital
The OMEGA Clinical Trial
Lebanon
Beirut : Rafic Hariri University Hospital
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
Lithuania
Alytus : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kaunas : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kedainiai : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Klaipeda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Panevezys : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Vilnius : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Netherlands
Alkmaar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Alkmaar : Medisch Centrum Alkmaar
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Amersfoort : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amstelveen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Amsterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Amsterdam : Academic Medical Center
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Amsterdam : Onze Lieve Vrouwe Gasthius
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Amsterdam : Academisch Medisch Centrum
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
Amsterdamn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Beek en Donk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Breda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Breda : Amphia Hospital
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Den Haag : Haga Ziekenhuis locatie Leyweg
The OMEGA Clinical Trial
Deventer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Doetinchem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Eindhoven : Catharina Ziekenhuis Eindhoven
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Eindhoven : Catharina Ziekenhuis
The OMEGA Clinical Trial
Enschede : Medisch Spectrum Twente
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Gouda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Groningen : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Haarlem : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hoorn : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leeuwarden : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Leeuwarden : Medisch Centrum Leeuwarden
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Maastricht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Meppel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nieuwegein : St. Antonius Ziekenhuis Nieuwegein
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Nijmegen : Canisius Wilhelmina Ziekenhuis
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Rotterdam : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Rotterdam : Maassstadziekenhuis Cardiology Research
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Sneek : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tiel : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Utrecht : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Venlo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
New Zealand
Auckland : Auckland City Hospital
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Norway
Ålesund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Elverum : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hamar : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Hønefoss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lillehammer : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Moss : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nesttun : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oslo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tønsberg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Trondheim : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tynset : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Puerto Rico
Manati : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Ponce : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
San Juan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Romania
Baia Mare : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Braila : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucharest : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bucuresti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Cluj-Napoca : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Craiova : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Iasi : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Oradea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Pitesti : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Sibiu : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Targu Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Tg. Mures : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Timisoara : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Russian Federation
Ekaterinburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Izhevsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kemerovo : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Moscow : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Petrozavodsk : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
S.-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saint-Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Saratov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St. Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
St.- Petersburg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Slovakia
Banska Bystrica : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bardejov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Bratislava : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Dubnica nad Vahom : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Dunajska Streda : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Galanta : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Komarno : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kosice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kralovsky Chlmec : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Levice : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nitra : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Nove Zamky : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Presov : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Velky Krtis : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Spain
Barcelona : Hospital Clinico Y Provincial
The OMEGA Clinical Trial
Lleida : Hospital Arnau de Vilanova
Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.
Sweden
Göteborg : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Kristianstad : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Luleå : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Malmö : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Östersund : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skanör : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skelleftea : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Skene : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Stockholm : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Uddevalla : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Vällingby : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Västerås : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Switzerland
Lausanne : Service de Chirurgie cardio-vasculaire CHUV
New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease
Taiwan
I-Lan : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Lin-Ko : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taichung : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
View More »
Taipei : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Yungkang : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
United Kingdom
London : King's College Hospital
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
United States
Washington : Novartis Investigative Site
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
